Seattle Genetics (NASDAQ: [[ticker:SGEN]]) said today that it achieved a milestone under its partnership with Bayer Schering Pharma AG of Germany. The Bothell, WA-based company provided Bayer with a license to its technology for linking antibodies to toxins, with a goal of making targeted and potent anti-cancer drugs. Bayer has now submitted an application to the FDA to start a clinical trial of a drug using the technology, Seattle Genetics said. Financial terms of the agreement weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
